Literature DB >> 9863027

Somatic genetic alterations in human malignant mesothelioma (review).

W C Lee1, J R Testa.   

Abstract

A review of cytogenetic and molecular genetic findings in human malignant mesotheliomas (MMs) is presented. The complex profile of somatic genetic changes characteristic of MMs implicates a multistep process of tumorigenesis in this malignancy. In particular, the occurrence of multiple, recurrent cytogenetic deletions in MMs suggests that loss and/or inactivation of tumor suppressor genes (TSGs) are critical to the development and progression of such tumors. Karyotypic and comparative genomic hybridization analyses of MMs have demonstrated frequent deletions of specific regions within chromosome arms 1p, 3p, 6q, 9p, 15q and 22q, and subsequent loss of heterozygosity (LOH) studies have documented high frequencies of allelic loss from each of these chromosomal sites. Positional candidate gene approaches have identified TSGs within two of these regions, i.e., p16/CDKN2A at 9p21 and NF2 at 22q12, which are frequently altered in MMs. Homozygous deletions appear to be the major mechanism affecting p16/CDKN2A, whereas inactivating mutations coupled with allelic loss occur at the NF2 locus. High density LOH analyses have pinpointed minimal regions of deletion in 1p, 3p, 6q, and 15q and are expected to facilitate efforts to identify putative TSGs at these locations which contribute to the pathogenesis of MMs.

Entities:  

Mesh:

Year:  1999        PMID: 9863027

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  9 in total

1.  Hemizygous loss of NF2 detected by fluorescence in situ hybridization is useful for the diagnosis of malignant pleural mesothelioma.

Authors:  Yoshiaki Kinoshita; Makoto Hamasaki; Masayo Yoshimura; Shinji Matsumoto; Akinori Iwasaki; Kazuki Nabeshima
Journal:  Mod Pathol       Date:  2019-06-23       Impact factor: 7.842

2.  Syntenic relationships between genomic profiles of fiber-induced murine and human malignant mesothelioma.

Authors:  Didier Jean; Emilie Thomas; Elodie Manié; Annie Renier; Aurélien de Reynies; Céline Lecomte; Pascal Andujar; Jocelyne Fleury-Feith; Françoise Galateau-Sallé; Marco Giovannini; Jessica Zucman-Rossi; Marc-Henri Stern; Marie-Claude Jaurand
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

Review 3.  Cellular and molecular parameters of mesothelioma.

Authors:  Maria E Ramos-Nino; Joseph R Testa; Deborah A Altomare; Harvey I Pass; Michele Carbone; Maurizio Bocchetta; Brooke T Mossman
Journal:  J Cell Biochem       Date:  2006-07-01       Impact factor: 4.429

4.  Spindle cell tumours of the pleura: a clinical, histological and comparative genomic hybridization analysis of 14 cases.

Authors:  Aija Knuuttila; Kowan J Jee; Eero Taskinen; Henrik Wolff; Sakari Knuutila; Sisko Anttila
Journal:  Virchows Arch       Date:  2005-09-17       Impact factor: 4.064

5.  Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).

Authors:  Thierry Jahan; Lin Gu; Robert Kratzke; Arkadiusz Dudek; Gregory A Otterson; Xiaofei Wang; Mark Green; Everett E Vokes; Hedy Lee Kindler
Journal:  Lung Cancer       Date:  2011-12-22       Impact factor: 5.705

6.  Reduced Fhit protein expression in human malignant mesothelioma.

Authors:  Lea Pylkkänen; Henrik Wolff; Tuula Stjernvall; Aija Knuuttila; Sisko Anttila; Kirsti Husgafvel-Pursiainen
Journal:  Virchows Arch       Date:  2003-10-16       Impact factor: 4.064

7.  Recombination and its roles in DNA repair, cellular immortalization and cancer.

Authors:  M A Shammas; R J Shmookler Reis
Journal:  Age (Omaha)       Date:  1999-04

8.  Tumor suppressor gene alterations in patients with malignant mesothelioma due to environmental asbestos exposure in Turkey.

Authors:  Esra Tug; Tuncer Tug; Halit Elyas; Mehmet Coskunsel; Salih Emri
Journal:  J Carcinog       Date:  2006-08-22

9.  p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression.

Authors:  J Creaney; B M McLaren; S Stevenson; A W Musk; N de Klerk; B W Robinson; R A Lake
Journal:  Br J Cancer       Date:  2001-01-05       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.